Aflibercept 8 mg Shows Long-Term Efficacy in Diabetic Macular Edema with Fewer Injections, shows trial
An extension of the PHOTON trial shows that aflibercept 8 mg maintains long-term visual and anatomical improvements in patients with diabetic macular edema (DME), allowing for extended dosing intervals and reduced injection frequency. Regeneron Pharmaceuticals has announced top-line, two-year (96 weeks) data for aflibercept 8 mg from the pivotal PHOTON trial in patients with diabetic macular […]